Where C16 Acylcarnitine (palmitoylcarnitine) is reported
Also listed as: Long-chain acylcarnitine
| Condition | Direction | Compared against | Associated symptoms | Source |
|---|---|---|---|---|
| ME/CFS | ↓ reduced | healthy controls | Impaired β-oxidation | Jinushi et al. 2023 (meta-analysis of pooled serum acylcarnitine; C16 not reported separately) |
Frequently asked questions
In which conditions is C16 Acylcarnitine (palmitoylcarnitine) altered?
In the OSMF atlas C16 Acylcarnitine (palmitoylcarnitine) is reported in ME/CFS. It is reduced in 1 across 1 entries.
Is there a standard clinical test for C16 Acylcarnitine (palmitoylcarnitine)?
The atlas entries for C16 Acylcarnitine (palmitoylcarnitine) do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.
Is one abnormal C16 Acylcarnitine (palmitoylcarnitine) result diagnostic?
No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.
Cite this page
Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.